Your browser doesn't support javascript.
loading
NRF2 activation promotes the recurrence of dormant tumour cells through regulation of redox and nucleotide metabolism.
Fox, Douglas B; Garcia, Nina Marie G; McKinney, Brock J; Lupo, Ryan; Noteware, Laura C; Newcomb, Rachel; Liu, Juan; Locasale, Jason W; Hirschey, Matthew D; Alvarez, James V.
Afiliação
  • Fox DB; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
  • Garcia NMG; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
  • McKinney BJ; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
  • Lupo R; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
  • Noteware LC; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
  • Newcomb R; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
  • Liu J; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
  • Locasale JW; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
  • Hirschey MD; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
  • Alvarez JV; Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition, Duke University Medical Center, Durham, NC, USA.
Nat Metab ; 2(4): 318-334, 2020 04.
Article em En | MEDLINE | ID: mdl-32691018
ABSTRACT
The survival and recurrence of dormant tumour cells following therapy is a leading cause of death in cancer patients. The metabolic properties of these cells are likely distinct from those of rapidly growing tumours. Here we show that Her2 down-regulation in breast cancer cells promotes changes in cellular metabolism, culminating in oxidative stress and compensatory upregulation of the antioxidant transcription factor, NRF2. NRF2 is activated during dormancy and in recurrent tumours in animal models and breast cancer patients with poor prognosis. Constitutive activation of NRF2 accelerates recurrence, while suppression of NRF2 impairs it. In recurrent tumours, NRF2 signalling induces a transcriptional metabolic reprogramming to re-establish redox homeostasis and upregulate de novo nucleotide synthesis. The NRF2-driven metabolic state renders recurrent tumour cells sensitive to glutaminase inhibition, which prevents reactivation of dormant tumour cells in vitro, suggesting that NRF2-high dormant and recurrent tumours may be targeted. These data provide evidence that NRF2-driven metabolic reprogramming promotes the recurrence of dormant breast cancer.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator 2 Relacionado a NF-E2 / Nucleotídeos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Nat Metab Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator 2 Relacionado a NF-E2 / Nucleotídeos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Nat Metab Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos